Pro-Pharma drug prevents mucositis

USA-based Pro-Pharmaceuticals says that a review of data from Phase I and II trials show that no mucositis serious adverse events were found  in patients treated with Davanat (mannose and galactose) and  chemotherapy that included fluorouracil.

With most cancer treatment, about 5% to 15% of patients get mucositis,  however, with 5-FU up to 40% contract mucositis and 10% to 15% get grade  3-4 oral mucositis. Yet, even in subjects with more than 100 cycles of  treatments with Davanat and 5-FU, none experienced gastrointestinal  SAEs.

"The data from the cancer patients in our clinical trials indicates  Davanat improves efficacy and reduces the side effects associated with  chemotherapy regimens," said chief executive Theodore Zucconi.